NeoGenomics, Inc.
NEOHealthcareNASDAQDiagnostics & Research
Scan Results
Daily timeframeNeoGenomics, Inc. operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. With a market capitalization of $2.16B, it sits in mid-cap territory. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories.
Market Cap
$2.16B
Beta
1.78
P/E (TTM)
—
P/E (Fwd)
48.41
EPS (TTM)
$-0.39
EPS (Fwd)
$0.34
ROE
-6.3%
ROA
-1.9%
Cash
$145.5M
Total Debt
$448.4M
Free CF
$43.9M
52W Change
55.5%
Annual Financials
Cash vs Debt
Where NEO stands vs its 150-day and 200-day moving averages
As of the October 9, 2026 close, NEO finished 26.24% above its 150-day moving average ($12.69) and 28.88% above its 200-day moving average ($12.43). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is NEO overbought or oversold?
At the October 9, 2026 close, NEO's RSI(14) was 28.6, in oversold territory (below 30). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
The company holds $145.5M in cash, though total debt stands at $448.4M. This level of leverage is common in the industry but worth monitoring as interest rate conditions evolve. Free cash flow comes in at $43.9M, providing flexibility for reinvestment, buybacks, or dividends. Consistent free cash flow generation is often considered a sign of operational health. ROE of -6.3% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. Revenue has grown from $509.7M (2022) to $727.3M (2025), reflecting a 43% increase over the period.
A beta of 1.78 means NEO is more volatile than average. Investors should be prepared for wider price swings relative to broader indices. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for NeoGenomics, Inc. and its sector.